LEUKAEMIA MICROENVIRONMENT & HIGH RISK CHILDHOOD LEUKAEMIA
With
Associate Professor Laurence Cheung
Curtin University
& Research Lead, Curtin Medical Research Institute,
Western Australia &
Research Lead,
The Kids Research Institute,
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Associate Professor Laurence Cheung is an exemplary pharmacist-scientist whose research is focused on improving outcomes in children with high-risk leukaemia.
He obtained his Bachelor of Pharmacy degree with First Class Honours from the Curtin University in 2000 and have been a registered pharmacist since 2001. In 2014, he completed the PhD studies at The Kids Research Institute Australia (The Kids) in the area of haematopoiesis and paediatric leukaemia.
He is now an Associate Professor at the Curtin Medical School as well as Curtin Medical Research Institute, and a Co-head of the Leukaemia Translational Research Laboratory at The Kids.
He has attracted over $8.7 million in research funding, including 16 awards as CIA (over $6.1 million). Assoc Prof Cheung was named the 2019 Cancer Council of WA Early Career Cancer Researcher of the Year and received the STEM Early Career Research Award at Curtin University in 2019.
Assoc Prof Cheung enjoys nurturing and motivating the next generation scientists and HDR students and he believes that the true success is about influencing others to achieve their own greatness.
He has supervised two PhD and one Masters students to completion, and is currently supervising 4 PhD students as a Primary Supervisor. In 2023, Assoc Prof Cheung received the Faulty of Health Sciences Teaching Excellence Individual Award for Honours, Postgraduate, or HDR supervision at Curtin University.
Funding sources include: Toby for Childhood Cancer, Cancer Council Western Australia, WA Government
Source: Supplied and adapted
https://orcid.org/0000-0001-6298-5288
-
Systems genetics to determine risk of developing diabetes complications
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Benefits of prehabilitation ahead of surgery
Dr Matthew Wallen PhD, AES, AEP is a Senior Research Fellow in Cancer Survivorship, the Deputy Lead of the Cancer Survivorship Program, and a Senior Lecturer in Exercise Science and Clinical Exercise Physiology within the College of Nursing and Health Sciences at Flinders University, in South Australia. His clinical interest focuses on improving outcomes for people requiring major surgery, specifically (1) lifestyle interventions, including exercise, nutritional, and psychological support to improve the health and wellbeing of people prior to surgery, termed ‘prehabilitation’, (2) novel physical function assessments aimed at identifying people at risk of treatment-related complications, and (3) implementation of new models of care in cancer.
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
